Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Durable responses to avelumab in patients with Merkel cell carcinoma

Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
Durable responses to avelumab in patients with Merkel cell carcinoma ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )
12 Apr 2017

Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses

Prof Peter Schmid - Barts Cancer Institute, London, UK
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses ( Prof Peter Schmid - Barts Cancer Institute, London, UK )
11 Apr 2017

Five-year follow-up of nivolumab in NSCLC

Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Five-year follow-up of nivolumab in NSCLC ( Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
11 Apr 2017

Mutations in cancer predisposition genes and risk for subsequent neoplasms

Dr Leslie Robison - St. Jude Children's Research Hospital, Memphis, USA
Mutations in cancer predisposition genes and risk for subsequent neoplasms ( Dr Leslie Robison - St. Jude Children's Research Hospital, Memphis, USA )
11 Apr 2017

Final overall survival analysis of MONARCH 1

Dr Hope Rugo - UCSF Medical Center, San Francisco, USA
Final overall survival analysis of MONARCH 1 ( Dr Hope Rugo - UCSF Medical Center, San Francisco, USA )
11 Apr 2017

Redefining tamoxifen for breast cancer

Gokul Das - Roswell Park Cancer Institute, Buffalo, USA
Redefining tamoxifen for breast cancer ( Gokul Das - Roswell Park Cancer Institute, Buffalo, USA )
11 Apr 2017

Olaparib and temozolomide for relapsed small cell lung cancer

Dr Anna Farago - Massachusetts General Hospital, Boston, USA
Olaparib and temozolomide for relapsed small cell lung cancer ( Dr Anna Farago - Massachusetts General Hospital, Boston, USA )
10 Apr 2017

Treatment choices for HER2 amplified colorectal cancer

Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy
Treatment choices for HER2 amplified colorectal cancer ( Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy )
10 Apr 2017

Final results of the HERACLES trial in HER2-amplified colorectal cancer

Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy
Final results of the HERACLES trial in HER2-amplified colorectal cancer ( Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy )
10 Apr 2017

Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumours

Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumours ( Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Apr 2017

Neratinib in HER2 or HER3 mutant solid tumours

Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA
Neratinib in HER2 or HER3 mutant solid tumours ( Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Apr 2017

Understanding response and resistance to cancer therapy: Lessons learned from melanoma

Dr Jennifer Wargo - The University of Texas MD Anderson Cancer Center, Houston, USA
Understanding response and resistance to cancer therapy: Lessons learned from melanoma ( Dr Jennifer Wargo - The University of Texas MD Anderson Cancer Center, Houston, USA )
10 Apr 2017